|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||2.81 / 24.00|
In recent trading, shares of Endocyte Inc have crossed above the average analyst 12-month target price of $23.33, changing hands for $23.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Stocks fall sharply on Thursday after a hawkish set of minutes from last month's Federal Reserve meeting cements the case for near-term interest rate hikes.
The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.
Dawn Svoronos, Former President of Merck's Europe/Canada Region, Brings Significant Commercial Leadership and Board Experience
Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?
Investors in Endocyte Inc saw new options begin trading this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.
A drug licensing agreement sent Endocyte skyrocketing.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.